Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. The acquisition is not going well. Despite deploying substantial marketing expenses, Xiidra's revenue is mediocre and declining.

Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner

Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuticals. Bausch + Lomb's CEO, the veteran Pharma dealmaker Brent Saunders, has praised the performance of the existing business and hinted at a focus on existing products and targeting growth.

Bausch + Lomb Corporation: Spin-Off Ready To Fly Troubled Nest And Find Upside

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C.

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders.

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc. With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on whether a rehearing will be granted within the next three months.

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with their healthcare providers to find the right management plan for them LAVAL, QC / ACCESSWIRE / May 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced award-winning actor, Bellamy Young, as the brand ambassador in a new campaign to raise awareness of Xifaxan, the first and only FDA approved medication to reduce the risk of overt hepatic encephalopathy (OHE) recurrence in adults. Overt hepatic encephalopathy is a complication of cirrhosis that can happen when the liver cannot filter toxins from the blood, and the toxins build up and reach the brain.

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

The eyecare specialist did not have a banner first quarter. It posted a surprise net loss for the period.

Why Bausch Health Companies Stock Dived by More Than 7% Today

Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participants Glen Santangelo - Jefferies Michael Nedelcovych - TD Cowen Douglas Miehm - RBC Capital Markets Umer Raffat - Evercore ISI Chi Fong - Bank of America David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings. Welcome to the Bausch Health first quarter 2024 earnings call.

Bausch Health Companies (BHC) Q1 2024 Earnings Call Transcript

Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.52 per share a year ago.

Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13% Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + Lomb Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financial results and other key updates from the quarter. "We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA.

Bausch Health Announces First Quarter 2024 Results

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

National HealthCare

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?

A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.

Bausch wins US appeal to block Alvogen generic of diarrhea drug

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029.

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through BC PharmaCare, the public drug program of British Columbia. ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46.

Pharma Stock Could Push Back Toward Highs

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of New York, LLC, Amneal EU, Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals, Inc. This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets. Amneal asserts that certain patents listed in the FDA's Orange Book for XIFAXAN® are unenforceable, invalid, and/or not infringed by Amneal's ANDA product.

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1 UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia. These first public drug plan listings for UCERIS come following the signing of a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) early this year, setting out the parameters for listing of the treatment by the public drug plans of the provinces, territories and federal government.

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report LAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today for IBS Awareness Month announced the results from the fourth edition of its annual survey of U.S adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). ​Developed as a nationwide survey conducted in partnership with Fairleigh Dickinson University Poll (FDU Poll), more than 850 IBS/CIC patients were surveyed to better understand their experiences.

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in Boston, April 5-8, 2024. Podium presentations include the results of studies evaluating the new TENEO Excimer Laser Platform, enVista and IC-8 Apthera intra.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma. An IIS is a study that is proposed, developed, and conducted by a qualified sponsor external to Bausch Health/Salix who assumes full responsibility for the study.

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

News for Bausch Health Companies Inc Stock (BHC)